1 completed, 1 recruiting, 1 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Recruiting 1, Terminated 1 |
Follow Refractory or Relapsed Solid Tumors: new trials by email Literature Review of Refractory or Relapsed Solid Tumors trials Research Report on Refractory or Relapsed Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction QLC5508 (Investigational Product / Formulation T), QLC5508 (Reference Product / Formulation R), Itraconazole - Refractory or Relapsed Solid Tumors | Phase 1 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 48 | 2026-06-09 | 2026-09-15 |
| Phase I/II Study of Avelumab in Pediatric Cancer Participants Avelumab - Refractory or Relapsed Solid Tumors, Lymphoma | Phase 1 | Terminated | EMD Serono Research & Development Institute, Inc. | 21 | 2018-03-07 | 2024-06-24 |
| Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors Sorafenib combined with Hydroxychloroquine - Refractory or Relapsed Solid Tumors | Phase 1 | Completed | The University of Texas Health Science Center at San Antonio | 18 | 2012-06-01 | 2016-03-25 |
Central Nervous System Neoplasms (1) · Lymphoma (1)
Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1)
Hydroxychloroquine (1) · Itraconazole (1) · Rifampin (1) · avelumab (1) · darolutamide (1)
EMD Serono Research & Development Institute, Inc. (1) · Qilu Pharmaceutical Co., Ltd. (1) · The University of Texas Health Science Center at San Antonio (1)
United States (2) · Belgium (1) · Canada (1) · China (1) · Denmark (1) · South Korea (1)
2017 (1)